Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-12-2017 | Clinical trial

Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema

Authors: David I. Kaufman, Chirag Shah, Frank A. Vicini, Marisa Rizzi

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Abstract

Background

This analysis was performed to assess the impact of early intervention following prospective surveillance using bioimpedance spectroscopy (BIS) to detect and manage breast cancer-related lymphedema (BCRL).

Methods

From 8/2010 to 12/2016, 206 consecutive patients were evaluated with BIS. The protocol included pre-operative assessment with L-Dex as well as post-operative assessments at regular intervals. Patients with L-Dex scores >10 from baseline were considered to have subclinical BCRL and were treated with over-the-counter (OTC) compression sleeve for 4 weeks. High-risk patients were defined as undergoing axillary lymph node dissection (ALND), receiving regional nodal irradiation (RNI), or taxane chemotherapy. Chronic BCRL was defined as the need for complex decongestive physiotherapy (CDP).

Results

Median follow-up was 25.9 months. Overall, 17% of patients had one high-risk feature, 8% two, and 7% had three. 9.8% of patients were diagnosed with subclinical BCRL with highest rates seen following ALND (23 vs. 7%, p = 0.01). Development of subclinical BCRL was associated with ALND and receipt of RNI. At last follow-up, no patients (0%) developed chronic, clinically detectable, BCRL. Subset analysis was performed of the 30 patients undergoing ALND. Median number of nodes removed was 18 and median number of positive nodes was 2. 77% received taxane chemotherapy, 62% axillary RT, and 48% had elevated BMI. Overall, 86% of patients had at least one additional high-risk feature, 70% at least two, and 23% had all three. Seven patients (23%) had abnormally elevated L-Dex scores at some point during follow-up. To date, none has required CDP.

Conclusions

The results of this study support prospective surveillance utilizing BIS initiated pre-operatively with subsequent post-operative follow-up measurements for the detection of subclinical BCRL. Intervention triggered by subclinical BCRL detection with an elevated L-Dex score was associated with no cases progressing to chronic, clinically detectable BCRL even in very high-risk patients.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefPubMed

Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010CrossRefPubMed

Gass J, Dupree B, Pruthi S et al (2016) Breast cancer survivorship: why, what, and when? Ann Surg Oncol 23:3162–3167CrossRefPubMed

Lawenda BD, Mondry TE, Johnstone PA (2009) Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 59:8–24CrossRefPubMed

International Society of Lymphology (2013) The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 46(1):1–11

Mohler ER, Mehara B. Clinical staging and conservative management of peripheral lymphedema. In Post TW, Rutgeerts P, Grover S (eds.), UpToDate. http://www.uptodate.com/contents/clinical-staging-and-conservative-management-of-peripheral-lymphedema?source=see_link

Shah C, Vicini FA (2011) Breast cancer-related arm lymphedema: incidence rates, diagnostic techniques, optimal management, and risk reduction strategies. Int J Radiat Oncol Biol Phys 81:907–914CrossRefPubMed

Gartner R, Jensen MB, Kronborg L et al (2010) Self-reported arm-lymphedema and functional impairment after breast cancer treatment—a nationwide study of prevalence and associated factors. The Breast 19:506–515CrossRefPubMed

Lee MJ, Beith J, Ward L et al (2014) Lymphedema following taxane-based chemotherapy in women early breast cancer. Lymphat Res Biol 12:282–288CrossRefPubMed

10.

Jung SY, Shin KH, Kim M et al (2014) Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat 148:91–98CrossRefPubMed

11.

National Comprehensive Cancer Network. Breast Cancer (Version 2.2016). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 17, 2017

12.

Soran A, Ozmen T, McGuire KP et al (2014) The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. Lymphat Res Biol 12:289–294CrossRefPubMed

13.

Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A et al (2010) Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ 340:b5396CrossRefPubMedPubMedCentral

14.

Stout Gergich NL, Pfalzer LA, McGarvey C et al (2008) Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 112:2809–2819CrossRefPubMed

15.

Cornish BH, Chapman M, Hirst C et al (2001) Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology 34:2–11PubMed

16.

Gaw R, Box R, Cornish B (2011) Bioimpedance in the assessment of unilateral lymphedema of a limb: the optimal frequency. Lymphat Res Biol 9:93–99CrossRefPubMed

17.

Shah C, Vicini FA, Arthur D (2016) Bioimpedance spectroscopy for breast cancer related lymphedema assessment: clinical practice guidelines. Breast J 22:645–650CrossRefPubMed

18.

Vicini F, Shah C, Lyden M et al (2012) Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer 12:133–137CrossRefPubMed

19.

Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307–316CrossRefPubMedPubMedCentral

20.

Donker M, van Tienhoven G, Straver M et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomized, multicentre, open-label, phase III non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRefPubMedPubMedCentral

21.

Lucci A, McCall LM, Beitsch PD et al (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25:3657–3663CrossRefPubMed

22.

Kuwajerwal NK, Feczko C, Dekhne N et al (2013) Comparison of lymphedema in patients with axillary lymph node dissections to those with sentinel lymph node biopsy followed by immediate and delayed ALND. Am J Clin Oncol 36:20–23CrossRef

23.

Ashikaga T, Krag DN, Land LR et al (2010) Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 102:111–118CrossRefPubMedPubMedCentral

24.

Deutsch M, Land S, Begovic M et al (2008) The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project Study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys 79:1020–1024CrossRef

25.

Wilke LG, McCall LM, Posther et al (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13:491–500CrossRefPubMed

26.

Coen JJ, Taghian AG, Kachnic LA et al (2002) Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 55:1209–1215

27.

Iyigun ZE, Duymaz T, Ilgun AS, et al. (2017) Preoperative lymphedema-related risk factors in early-stage breast cancer. Lymphat Res Biol

28.

Dylke ES, Schembri GP, Bailey DL et al (2016) Diagnosis of upper limb lymphedema: development of an evidence-based approach. Act Oncologica 55:1477–1483CrossRef

29.

Fu M, Cleland C, Guth A et al (2013) L-Dex ratio in detecting breast cancer-related lymphedema:reliability, sensitivity and specificity. Lymphology 46:85–96PubMedPubMedCentral

30.

Box RC, Reul-Hirche HM, Bullock-Saxton JE et al (2002) Physiotherapy after breast cancer surgery: results of a randomized controlled study to minimise lymphedema. Breast Cancer Res Treat 75:51–64CrossRefPubMed

31.

Nielsen HM, Friis RB, Linnet S et al (2017) Loco-regional morbidity after breast conservation and axillary lymph node dissection for early breast cancer with or without regional nodes radiotherapy, perspectives in modern breast cancer treatment: the Skagen Trial 1 is active. Acta Oncologica 56(5):713–718CrossRefPubMed

32.

Kilbreath SL, Rfshauge KM, Beith JM et al (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29–36CrossRefPubMed

33.

Soran A, Menekse E, Girgis M et al (2016) Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work? Support Care Cancer 24:1413–1419CrossRefPubMed

34.

Guenzi M, Blandino G, Vidili M et al (2015) Hypofractionated irradiation of infra-supraclavicular lymph nodes after axillary dissection in patients with breast cancer post-conservative surgery: impact on late toxicity. Radiat Oncol 10:177CrossRefPubMedPubMedCentral

35.

36.

Ridner SH, Shah C, Dietrich MS, et al. (2017) A randomized trial evaluating bioimpedance spectroscopy vs. tape measurement in the prevention of lymphedema following breast cancer treatment. Poster session presented at the San Antonio Breast Cancer Conference, San Antonio, TX

Title: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema
Authors: David I. Kaufman
Chirag Shah
Frank A. Vicini
Marisa Rizzi
Publication date: 01-12-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4451-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Impact of rheumatoid arthritis on radiation-related toxicity and cosmesis in breast cancer patients: a contemporary matched-pair analysis

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society

BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells

BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women

Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer